Tuesday, 26 September 2017

Gilead Sciences Loses 200 Million Dollar Case to Merck

Gilead Sciences is a bio-pharmaceutical research and development company that discovers, develops and commercializes innovative medicines in areas of unmet medical need.  Recently, Gilead lost a patent infringement case to Merck, another pharmaceuticals company, and was ordered to pay $200 million in royalties for a pair of hepatitis C drugs, Sovaldi and Harvoni.  The combined […]

The post Gilead Sciences Loses 200 Million Dollar Case to Merck appeared first on Rogers DVS, written by Graham Rogers DVS. http://ift.tt/2hup84n



via Tumblr http://ift.tt/2xy0dB3

No comments:

Post a Comment